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Abstract
Introduction: Studies suggest that high circulating levels of prolactin increase breast cancer risk. It is unclear if
genetic variations in prolactin (PRL) or prolactin receptor (PRLR) genes also play a role. Thus, we examined the
relationship between single nucleotide polymorphisms (SNPs) in PRL and PRLR, serum prolactin levels and breast
cancer risk in a population-based case-control study.
Methods: We genotyped 8 PRL and 20 PRLR tag SNPs in 1965 breast cancer cases and 2229 matched controls,
aged 20-74, and living in Warsaw or Łódź, Poland. Serum prolactin levels were measured by immunoassay in a
subset of 773 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) for genotype associations with breast
cancer risk were estimated using unconditional logistic regression, adjusted for age and study site. Geometric
mean prolactin levels were estimated using linear regression models adjusted for age, study site, blood collection
time, and menstrual cycle day (premenopausal women).
Results: Three SNPs were associated with breast cancer risk: in premenopausal women, PRLR rs249537 (T vs. C per-
allele OR 1.39, 95% CI 1.07 - 1.80, P = 0.01); and in postmenopausal women, PRLR rs7718468 (C vs. T per-allele OR
1.16, 95% CI 1.03 - 1.30, P = 0.01) and PRLR rs13436213 (A vs. G per-allele OR 1.13 95% CI 1.01 - 1.26, P = 0.04).
However, mean serum prolactin levels for these SNPs did not vary by genotype (P-trend > 0.05). Other SNPs were
associated with serum prolactin levels: PRLR rs62355518 (P-trend = 0.01), PRLR rs10941235 (P-trend = 0.01), PRLR
rs1610218 (P-trend = 0.01), PRLR rs34024951 (P-trend = 0.02), and PRLR rs9292575 (P-trend = 0.03) in
premenopausal controls and PRL rs849872 (P-trend = 0.01) in postmenopausal controls.
Conclusions: Our data provide limited support for an association between common variations in PRLR and breast
cancer risk. Altered serum prolactin levels were not associated with breast cancer risk-associated variants,
suggesting that common genetic variation is not a strong predictor of prolactin-associated breast cancer risk in this
population.
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The reproductive hormone prolactin is produced pri-
marily by the pituitary gland and in lesser amounts by
several other tissues, including breast tissue. Prolactin
plays a central role in breast development, differentia-
tion, and lactation (reviewed in [1]), but experimental
data suggest that, in addition to having a role in nor-
mal development, prolactin may have procarcinogenic
effects (reviewed in [2,3]). Prolactin and prolactin
receptors are present in normal breast tissue, benign
breast disease, breast cancer cell lines, and breast
tumor tissue [3-7], leading to speculation that the pro-
liferative and antiapoptotic effects of prolactin in
breast epithelial cells could be a factor in breast carci-
nogenesis [2,8].
There is a growing body of epidemiologic evidence
supporting an association between circulating prolactin
levels and breast cancer risk, although data are not con-
clusive. Large prospective studies have reported a posi-
tive association between prolactin levels and breast
cancer risk [9-11]. No association was reported by smal-
ler prospective studies, although the number of breast
cancer cases was limited [12,13]. Results from case-con-
trol studies are inconsistent (reviewed in [14]). We
recently reported that higher prolactin levels were asso-
ciated with increased breast cancer risk in our popula-
tion-based case-control study conducted in Poland [15],
and this is consistent with larger cohort studies. We
also found that increased serum prolactin levels were
associated with nulliparity in premenopausal women
and with current or recent use of hormone therapy
(HT) and lower body mass indices (BMIs) in postmeno-
pausal women [15].
In addition to reproductive and environmental fac-
tors, genetic variation in the prolactin (PRL)a n dp r o -
lactin receptor (PRLR) genes may be associated with
increased prolactin levels and breast cancer risk.
Exploration of genetic variants in PRL and PRLR has
identified single-nucleotide polymorphisms (SNPs) that
alter transcription factor binding [16], modify prolactin
receptor activity [17,18], and may be associated with
breast cancer risk [19,20] or circulating prolactin levels
[19]. To follow up our previous finding of a relation-
ship between serum prolactin and breast cancer risk
[15], we investigated the association between common
genetic variation in PRL and PRLR and breast cancer
risk in the Polish Breast Cancer Study. Additionally,
we examined the association between PRL and PRLR
SNPs and serum prolactin levels among controls,
hypothesizing that altered serum prolactin levels may
be an intermediate marker between genetic variation
in PRL and PRLR and breast cancer risk.
Materials and methods
Study population
The design of the Polish Breast Cancer Study has been
reported [15,21]. Briefly, eligible cases included women
(age range of 20 to 74 years) who were living in the
cities of Łódź or Warsaw, Poland, and whose primary
invasive or in situ breast cancer was diagnosed between
2000 and 2003. Cases were identified by means of a
rapid identification system at area hospitals, and the
Warsaw Cancer Registry was used to identify any addi-
tional cases that were missed by the rapid identification
system. Eligible controls were identified from a popula-
tion registry containing demographic information for all
residents of Poland and were frequency-matched to
cases on the basis of age (5-year categories) and study
site. All participants provided informed consent, and the
study protocol was approved by ethics committees in
Poland and the US. A total of 2,386 cases (79% of eligi-
ble) and 2,502 controls (69% of eligible) were enrolled
in the study.
Study participants provided information on demo-
graphics, reproductive and medical history, oral contra-
ceptive and postmenopausal hormone use, and other
potential breast cancer risk factors during a personal
interview. Height, weight, and waist and hip circumfer-
ences were measured by a trained nurse. A blood sam-
ple was provided by 84% of cases and 92% of controls.
Genotyping
Tag SNPs in PRL and PRLR were genotyped by using
the Fluidigm dynamic array at the National Cancer
Institute (NCI) Core Genotyping Facility (Frederick,
MD, USA) [22]. SNPs were selected by using genotype
data from the International HapMap Project CEU (Utah
residents with Northern and Western European ancestry
from the CEPH (Centre d’Etude du Polymorphisme
Humain) collection) population. SNPs with a minimum
minor allele frequency (MAF) of 0.05 were chosen to
cover the genes with a minimum pairwise correlation
(r
2) of 0.80. Tag SNP selection was performed by using
Tagger in Haploview (Broad Institute, Cambridge, MA,
USA). SNPs previously reported by Lee and colleagues
[19] to be associated with serum prolactin levels or
breast cancer risk were also genotyped and were used as
tag SNPs where possible. Thirty-four tag SNPs were
selected for study; six were excluded because of assay
design issues. Four thousand two hundred twenty-one
participants had adequate DNA available for Fluidigm
genotyping, and genotype calls were made for 3,849
(91%).
Two SNPs (rs2244502 and rs4425481) failed the Flui-
digm genotyping and were repeated by using Taqman
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pants had adequate DNA for Taqman genotyping, and
genotype calls were made for 4,047 (96%).
A total of 28 tag SNPs - 8 PRL and 20 PRLR -w e r e
genotyped in 1,965 cases and 2,229 controls, whose
characteristics are displayed in Table 1. PRL SNP
rs9466314 was monomorphic and excluded from further
analysis. Genotype frequencies for two PRLR SNPs were
not consistent with Hardy-Weinberg equilibrium (HWE)
in controls (defined as P < 0.001: rs7731880 and
rs12153280) and these SNPs were also excluded from
the analysis. Associations with serum prolactin and
breast cancer risk were examined for the remaining 25
SNPs. Linkage disequilibrium (LD) among control
Table 1 Characteristics of Polish Breast Cancer Study participants (n = 4,194)
Characteristic Case Control P value
a
Number Percentage Number Percentage
Age
Less than 40 years 80 4 92 4
40-49 years 501 26 554 25
50-59 years 668 34 759 34
60-69 years 508 26 588 26
At least 70 years 208 11 236 11
Menopausal status
Premenopausal 521 27 686 31 <0.01
Postmenopausal 1,444 73 1,543 69
Parity
Nulliparous 283 14 248 11 <0.01
Parous 1,682 86 1,981 89
Breastfeeding
b
0 months 353 21 368 19 0.03
Less than 12 months 939 56 1,078 54
12 to 23 months 255 15 336 17
At least 24 months 135 8 199 10
Age at menarche
Not more than 12 years 562 29 497 23 <0.01
13 years 427 22 516 23
14 years 520 27 615 28
15 years 208 11 253 11
At least 16 years 233 12 322 15
Body mass index
Less than 25 kg/m
2 732 37 705 32 <0.01
25 to less than 30 kg/m
2 696 35 812 36
At least 30 kg/m
2 535 27 709 32
Oral HT use
c
Never 1,106 82 1,284 88 <0.01
Current 120 9 68 5
Recent 64 5 25 2
Past 62 5 83 6
Alcohol drinks per week
Never drinker 1,254 65 1,464 67 0.11
0 to less than 1 184 10 206 9
1 to less than 3 282 15 289 13
3 to less than 5 71 4 97 4
At least 5 137 7 121 6
Family history of breast cancer
d
No 1,766 90 2,101 94 <0.01
Yes 198 10 128 6
aPearson chi-square test P value.
bParous women only.
cHT, hormone therapy, postmenopausal women only.
dMother, sister, daughter, excludes half-sisters.
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2values were 0.21 (range
of 0 to 0.84) among sequential PRL SNPs and 0.13
(range of 0 to 0.45) among PRLR SNPs. Additional posi-
tional information and allele frequencies are presented
in Table 2.
SNP genotyping completion proportions ranged from
88% to 98%. To confirm the accuracy of genotype calls,
152 samples were genotyped in duplicate. Concordance
between duplicate samples was less than 98% for three
SNPs - rs62355518 (97%), rs7734558 (96%), and
rs7735260 (82%) - and at least 98% for the remaining
SNPs.
Serum prolactin measurement
Serum prolactin concentration was measured in a subset
of cases and controls, whose selection was described in
detail by Faupel-Badger and colleagues [15]. Controls
were matched to cases by menopausal status, age
(5-year categories), time of blood collection (within 2
hours), study site, and day of menstrual cycle (within 2
days, premenopausal women only). Only control prolac-
tin concentrations were used in this analysis.
Serum prolactin levels were measured by Quest Diag-
n o s t i c s( S a nJ u a nC a p i s t r a n o ,C A ,U S A )b yu s i n gt h e
Bayer ADVIA Centaur immunoassay (Bayer HealthCare,
Tarrytown, NY, USA) and were calculated after calibra-
tion with known prolactin concentrations. One control
subject was excluded from further serum prolactin ana-
lyses because of a concentration outside the assay limits
of detection (0.3 to 200 ng/mL). The within-batch coef-
ficient of variation (CV) was 3.84% and the between-
batch CV was 2.31%, as reported previously [15].
Covariates
Age was defined as age at diagnosis for cases or as age
at interview for controls and was included in models
Table 2 PRL and PRLR single-nucleotide polymorphisms genotyped in the Polish Breast Cancer Study
Single-nucleotide polymorphism Chromosome Base pair coordinate
a Location Alleles MAF
b PHWE
c
PRLR
rs37364 5 35108137 Intron 7 A/C 0.21 0.58
rs43215 5 35122726 Intron 3 G/A 0.12 0.67
rs249537 5 35125057 Intron 3 C/T 0.11 3.0 × 10
-3
rs7734558 5 35150368 Intron 3 C/T 0.48 0.03
rs62355518 5 35218778 Intron 3 A/G 0.16 0.68
rs10941235 5 35221337 Intron 3 G/A 0.27 0.49
rs13436213 5 35221583 Intron 3 G/A 0.35 1
rs4425481 5 35221654 Intron 3 G/T 0.06 0.20
rs1610218 5 35222451 Intron 3 G/A 0.04 0.63
rs17249539 5 35233127 Intron 3 C/G 0.12 0.79
rs12153280 5 35235019 Intron 3 G/T 0.11 <1.0 × 10
-4
rs873456 5 35235414 Intron 3 G/T 0.34 0.90
rs7718468 5 35236793 Intron 3 T/C 0.32 0.53
rs34024951 5 35246079 Intron 3 G/A 0.10 0.95
rs9292575 5 35250262 Intron 3 C/A 0.09 0.74
rs10038062 5 35256276 Intron 3 A/G 0.09 0.76
rs7731880 5 35257203 Intron 3 G/C 0.12 <1.0 × 10
-4
rs931741 5 35257808 Intron 3 C/G 0.31 0.83
rs7735260 5 35262772 Intron 3 C/T 0.16 4.9 × 10
-3
rs10068521 5 35266137 Exon 1 C/G 0.03 0.42
PRL
rs849872 6 22391011 3’ UTR A/G 0.15 0.60
rs849870 6 22391864 3’ UTR G/A 0.14 0.56
rs1205960 6 22396139 3’ UTR G/A 0.25 0.13
rs849886 6 22399346 Intron 3 G/A 0.46 0.94
rs2244502 6 22402966 Intron 3 A/T 0.31 0.23
rs12202764 6 22403312 Intron 3 A/T 0.27 0.16
rs3756824 6 22406716 5’ G/C 0.03 0.07
rs9466314 6 22414284 5’ T/T 0 1
aSingle-Nucleotide Polymorphism database (dbSNP) build 36.3.
bMinor allele frequency in controls only.
cTest of Hardy-Weinberg equilibrium in controls only. PRL,
prolactin (gene); PRLR, prolactin receptor (gene); UTR, untranslated region.
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menopausal if they reported that they were still having
natural menstrual periods; medical records were used to
determine menopausal status for women who did not
know whether they were still experiencing natural men-
strual periods.
Among parous women, breastfeeding duration was the
sum of the number of months of reported breastfeeding
for each child. Among postmenopausal women, oral HT
use was based on self-reported use of estrogen and pro-
gesterone pills for purposes other than birth control and
classified as never-use (<1 month use), current use (≥1
month use and last use up to 6 months ago), recent use
(≥1 month use and last use from 6 months up to 2
years ago), and past use (≥1 month use and last use at
least 2 years ago). Family history of breast cancer was
based on female first-degree relatives with breast cancer.
Age at menarche, highest level of education, and num-
ber of alcoholic drinks per week were also based on
self-report.
BMI (in kilograms per square meter) was calculated
from height and weight measurements and included in
models as a categorical variable (<25 kg/m
2,2 5t o< 3 0
kg/m
2,a n d≥30 kg/m
2). Time of blood collection was
included in models by using 2-hour categories. Time
since last menstrual period was the number of days
between blood draw and the participant’s most recent
menstrual period and was used as a continuous variable.
Statistical analysis
Odds ratios (ORs), 95% confidence intervals (CIs), and
Wald P values for the association between genotypes
and breast cancer were estimated by using unconditional
logistic regression, adjusting for study site and age. The
more common allele was used to determine the refer-
ence group. Per-allele ORs and P values for trend were
estimated by using a log-additive (one degree of free-
dom) statistical model. Genotype-specific ORs were esti-
mated using the co-dominant (two degrees of freedom)
model.
Haplotype associations for breast cancer risk were
explored by using Haplostats [23,24]. For each gene, a
score test was used to generate a global P value for the
overall association between haplotypes and breast can-
cer by using the sliding window approach with a
three-SNP window. ORs, 95% CIs, and P values were
estimated for individual haplotypes with a frequency of
5% or greater within regions where haplotypes were
globally associated with breast cancer (score test global
P < 0.05). Haplotype effects were modeled as log-addi-
tive by using logistic regression and were adjusted for
a g ea n ds t u d ys i t e .
Serum prolactin levels were log-transformed, and lin-
ear regression was used to estimate geometric mean
prolactin levels by genotype in controls and to estimate
the association between genotypes or haplotypes and
serum prolactin levels. Previous studies have shown that
prolactin levels are higher in premenopausal compared
with postmenopausal women and that prolactin levels
vary with the day of menstrual cycle in premenopausal
women [25,26]. Owing to the differences in average pro-
lactin levels and cycling patterns, we presented data on
mean prolactin levels by genotype stratified by meno-
pausal status. Models were adjusted for age, time of
blood collection, and time since last menstrual period
(premenopausal women only). Additional models that
adjusted for factors previously determined to be asso-
ciated with prolactin levels in this study population -
parity in premenopausal women and oral HT use and
BMI in postmenopausal women - were constructed [15].
Associations between SNPs and breast cancer risk are
shown stratified by menopausal status for direct com-
parison with mean prolactin levels by genotype and are
also presented for all women combined.
Statistical tests were two-sided (alpha = 0.05). Unad-
justed P values are presented in all tables. We also eval-
uated the false discovery rate (FDR) by using the
Benjamini and Hochberg method [27] to assess the
robustness of associations after accounting for multiple
comparisons. Statistical analyses were performed by
using SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA) and R version 2.10.
Results
Participant characteristics
The mean age of participants was 56 years, and 73% of
cases and 69% of controls were postmenopausal. The
majority of cases and controls were parous (cases 86%,
controls 89%), reported having breastfed (cases 79%,
controls 81%), and never drank alcohol (cases 65%, con-
trols 67%) (Table 1). Most postmenopausal participants
reported that they had never used oral HT (cases 82%,
controls 88%) (Table 1). Cases reported a family history
of breast cancer more often than controls (cases 10%,
controls 6%) (Table 1).
Association between PRL and PRLR SNPs and breast
cancer risk
We examined the association between variant alleles in
25 SNPs - 7 PRL and 18 PRLR - and breast cancer risk.
PRLR SNPs rs7718468 and rs13436213 were associated
with postmenopausal breast cancer risk (rs7718468 per-
allele OR 1.16, 95% CI 1.03 to 1.30; rs13436213 per-
allele OR 1.13, 95% CI 1.01 to 1.26). For both SNPs, the
association was strongest for women carrying the minor
allele homozygous genotype (Table 3). One SNP was
associated with premenopausal breast cancer: PRLR
rs249537 (per-allele OR 1.39, 95% CI 1.07 to 1.82).
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menopausal status
a
Single-nucleotide polymorphism Case Control OR (95% CI)
b P Mean prolactin in sampled controls
c, ng/mL (95% CI) P trend
All subjects
PRLR rs249537
CC 1,331 1,540 Referent
CT 388 400 1.12 (0.96-1.32) 0.15
TT 19 10 2.19 (1.02-4.73) 0.05
T vs. C 1.17 (1.01-1.35) 0.04
PRLR rs13436213
GG 698 829 Referent
AG 814 885 1.09 (0.95-1.26) 0.21
AA 237 238 1.18 (0.96-1.46) 0.11
A vs. G 1.09 (0.99-1.20) 0.08
PRLR rs7718468
TT 739 895 Referent
CT 771 831 1.12 (0.98-1.29) 0.10
CC 214 209 1.24 (1.00-1.54) 0.05
C vs. T 1.12 (1.01-1.23) 0.02
Premenopausal
PRLR rs249537
CC 351 492 Referent 5.50 (4.05-7.47)
CT 104 122 1.19 (0.88-1.59) 0.26 5.51 (3.86-7.87)
TT 12 2 8.42 (1.89-37.9) 0.01 3.83 (1.36-10.82)
T vs. C 1.39 (1.07-1.80) 0.01 0.84
PRLR rs13436213
GG 196 269 Referent 5.35 (3.90-7.33)
AG 220 265 1.14 (0.88-1.48) 0.32 5.30 (3.83-7.32)
AA 55 82 0.92 (0.62-1.36) 0.67 5.40 (3.75-7.80)
A vs. G 1.01 (0.85-1.20) 0.92 0.98
PRLR rs7718468
TT 204 286 Referent 5.79 (4.22-7.94)
CT 209 250 1.18 (0.91-1.53) 0.21 5.46 (3.90-7.64)
CC 50 72 0.97 (0.65-1.46) 0.90 5.21 (3.6-7.54)
C vs. T 1.05 (0.87-1.25) 0.63 0.31
Postmenopausal
PRLR rs249537
CC 980 1,048 Referent 6.36 (5.01-8.07)
CT 284 278 1.11 (0.92-1.34) 0.28 6.45 (4.99-8.33)
TT 7 8 0.94 (0.34-2.61) 0.90 6.42 (3.64-11.32)
T vs. C 1.09 (0.92-1.31) 0.33 0.81
PRLR rs13436213
GG 502 560 Referent 6.29 (4.97-7.95)
AG 594 620 1.07 (0.91-1.27) 0.40 6.52 (5.15-8.25)
AA 182 156 1.32 (1.03-1.68) 0.03 6.48 (5.01-8.39)
A vs. G 1.13 (1.01-1.26) 0.04 0.48
PRLR rs7718468
TT 535 609 Referent 6.47 (5.09-8.22)
CT 562 581 1.11 (0.94-1.31) 0.21 6.86 (5.39-8.74)
CC 164 137 1.39 (1.07-1.79) 0.01 6.41 (4.89-8.4)
C vs. T 1.16 (1.03-1.30) 0.01 0.56
aA complete list of single-nucleotide polymorphism associations with breast cancer risk can be found in Supplementary table S2 in Additional file 1.
bOdds ratio
(OR) and confidence interval (CI) adjusted for age and study site.
cAdjusted for age, study site, time of blood collection, and time since last period
(premenopausal only). PRLR, prolactin receptor (gene).
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prolactin levels in controls
Serum prolactin was measured in 773 controls, and levels
were higher in premenopausal women compared with
postmenopausal women (Figure 1). Several SNPs in PRLR
were significantly associated with prolactin levels in preme-
nopausal controls: rs62355518 (P = 0.01), rs10941235 (P =
0.01), rs1610218 (P = 0.01), rs34024951 (P =0 . 0 2 ) ,a n d
rs9292575 (P = 0.03) (Table 4). Results were similar after
adjustment for additional factors related to prolactin levels
in controls (Supplementary table S3a in Additional file 1).
In postmenopausal controls, the G allele of PRL
rs849872 was associated with higher serum prolactin
levels (P = 0.01) (Table 4). Closer examination of the pro-
lactin distributions showed that there were several outlier
values among postmenopausal controls (Figure 1), and so
we performed a sensitivity analysis to determine the
effect of these outliers on the association between
rs849872 and prolactin in postmenopausal controls; the
association was no longer significant after excluding the
seven prolactin values greater than 30 ng/mL (P = 0.09).
In addition, visual examination of the data shows that the
distribution of prolactin concentrations was similar by
genotype (Supplementary figure S1 in Additional file 2).
Association between PRL and PRLR haplotypes, serum
prolactin, and breast cancer risk
A sliding window approach was used to identify global
haplotype associations with breast cancer. An
association was detected for a region encompassing
PRLR SNPs rs873456, rs7718468, rs34024951, and
rs9292575 and postmenopausal breast cancer. Five hap-
lotypes in this region had estimated frequencies of
greater than 0.05, and haplotype G-C-G-C was positively
associated with breast cancer risk when compared with
the referent haplotype G-T-G-C (per-copy OR 1.17, 95%
CI 1.02 to 1.34) (Supplementary table S1 in Additional
file 1). These haplotypes were not associated with serum
prolactin levels in postmenopausal controls (data not
shown). There was no association between PRLR haplo-
types and premenopausal breast cancer or between PRL
haplotypes and premenopausal or postmenopausal
breast cancer.
We used the FDR method to evaluate the robustness
of SNP associations with serum prolactin levels and
breast cancer risk. When all 25 SNPs tested were
accounted for, FDR-adjusted P values for SNPs with a
nominal P v a l u eo fl e s st h a n0 . 0 5r a n g e df r o m0 . 1 0t o
0.69.
Discussion
We examined the association between SNPs in PRL and
PRLR and breast cancer risk in a population of Polish
women. PRLR SNPs rs7718468 and rs13436213 and a
haplotype including PRLR SNPs rs873456, rs7718468,
rs34024951, and rs9292575 were associated with breast
cancer in postmenopausal women; however, the SNP
associations were not statistically significant after adjust-
ment for multiple comparisons. PRLR rs249537 was
associated with breast cancer risk in premenopausal
women; however, the minor allele homozygote genotype
for rs249537 was rare (<1% in controls) and this associa-
tion requires replication.
Few studies have investigated the association between
SNPs in PRL and PRLR and breast cancer risk. Lee and
colleagues [19] evaluated the association between PRL
and PRLR tag SNPs and breast cancer risk in a case-
control analysis of approximately 3,500 multiethnic pre-
menopausal and postmenopausal women and reported
that PRL rs9466314 was associated with increased breast
cancer risk and that PRLR rs34024951 was associated
with decreased risk. rs34024951 was not associated with
premenopausal or postmenopausal breast cancer in our
study population but, along with rs7718468, was a mem-
ber of a four-SNP haplotype that was associated with
postmenopausal breast cancer risk. This suggests that
the region marked by rs34024951 and rs7718468 may
be in LD with a breast cancer risk-associated locus.
Neither rs34024951 nor rs7718468 or the PRLR haplo-
type was associated with serum prolactin levels in post-
menopausal controls in our study; thus, our data do not
support the hypothesis that the risk mechanism is linked
to circulating prolactin levels.
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Figure 1 The distribution of serum prolactin concentrations in
controls, by menopausal status. Prolactin concentrations in Polish
Breast Cancer Study control subjects ranged from 2.1 to 348.4 ng/
mL, and the majority were less than 50 ng/mL. The unadjusted
geometric mean (interquartile range) prolactin concentrations were
10.89 ng/mL (7.80 to 15.30) in premenopausal controls and 6.99 ng/
mL (5.30 to 8.60) in postmenopausal controls.
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breast cancer risk was limited by population differences in
risk allele frequencies. The population studied by Lee and
colleagues [19] included multiple ethnic groups, and the
rs9466314 risk allele was somewhat common (5% in con-
trols) among African-Americans only; in whites, the risk
allele was extremely uncommon (<0.25% in controls).
Similarly, rs9466314 was monomorphic in our study, and
we were unable to examine the association. Interestingly,
the risk allele frequencies for both rs9466314 and
rs34024951 were higher in African-Americans compared
with other ethnic groups in the analysis by Lee and collea-
gues, suggesting that there may be a greater chance of dis-
covery of PRL and PRLR SNPs related to breast cancer
risk in African-American or African populations.
Comparison with other studies was also limited by a
lack of overlapping SNPs between the studies. None of
the SNPs we found to be associated with breast cancer
(rs249537, rs7718468, and rs13436213) was included in
the analysis by Lee and colleagues [19]. SNPs in LD
with rs249537 and 13436213 were not associated with
breast cancer in the analysis by Lee and colleagues. No
nearby SNPs were in LD with rs7718468 in the HapMap
CEU population; therefore, we were unable to check the
associations of correlated SNPs in other studies.
In another study, Vaclavicek and colleagues [20]
reported that PRL promoter SNPs rs1341239 and
rs12210179 were positively associated with familial
breast cancer. SNP rs12202764, which is in LD with
rs12210179, was not associated with breast cancer in
our study. SNP rs1341239 was initially selected for gen-
otyping but failed assay design; SNPs in LD with
rs1341239 were not genotyped in our study. A positive
nonsignificant association between PRL rs2244502 and
familial breast cancer was also reported in the same
study [20], but rs2244502 was not associated with breast
cancer in our study.
In vitro studies have described polymorphisms in
PRLR - I76V (rs16871473) and I146L (rs72478580) -
[17,18,28] that result in constitutive activation of the
Table 4 Single-nucleotide polymorphisms associated with serum prolactin levels in the Polish Breast Cancer Study
a
Single-nucleotide polymorphism Number Geometric mean
b 95% CI P trend
Premenopausal controls
PRLR
rs62355518
AA 140 11.16 8.81-14.15 0.01
AG 55 8.90 6.87-11.51
GG 5 10.61 6.60-17.05
rs10941235
GG 101 11.05 8.66-14.08 0.01
AG 90 9.24 7.21-11.85
AA 12 9.37 6.57-13.37
rs1610218
GG 192 10.47 8.26-13.28 0.01
AG 13 6.95 4.81-10.03
AA 0
rs34024951
GG 170 10.25 8.07-13.02 0.02
AG 34 8.38 6.27-11.19
AA 1 6.60 2.53-17.21
rs9292575
CC 162 10.07 7.97-12.71 0.03
AC 39 13.38 10.10-17.72
AA 3 7.32 4.19-12.80
Postmenopausal controls
PRL
rs849872
AA 300 7.63 6.23-9.35 0.01
AG 126 8.34 6.76-10.28
GG 13 9.69 7.10-13.24
aA complete list of single-nucleotide polymorphism associations with serum prolactin concentrations can be found in Supplementary tables S3a and S3bi n
Additional file 1.
bAdjusted for age, study site, time of blood collection, and time since last period (premenopausal only). CI, confidence interval; PRL, prolactin
(gene); PRLR, prolactin receptor (gene).
Nyante et al. Breast Cancer Research 2011, 13:R42
http://breast-cancer-research.com/content/13/2/R42
Page 8 of 11prolactin receptor. Three small studies suggest that
these polymorphisms may be more prevalent among
women with benign breast disease, a breast cancer risk
factor. The prevalence rates of I146L were 6% among
white women with benign breast disease and 0% among
non-white women with benign breast disease and
healthy women [17,28]. The prevalence rates of the
I76V variant allele were 7% in whites and 22% in non-
whites with benign breast disease and 4% in a group of
healthy women [18]. To our knowledge, there are no
data relating these variants to serum prolactin levels or
breast cancer risk. I146L and I76V polymorphisms were
not genotyped in the Polish Breast Cancer Study, but
these loci may represent appealing targets for future
research into PRLR genetic variation and breast cancer
risk.
Our data did not support the hypothesis that serum
prolactin levels differ for women with PRL and PRLR
genotypes associated with breast cancer; prolactin levels
did not vary by genotype for any of the breast cancer-
associated SNPs in this study (rs13436213, rs249537,
and rs7718468). To our knowledge, only Lee and collea-
gues [19] have examined serum prolactin levels in con-
junction with PRL and PRLR genotypes and breast
cancer risk, but examination of serum prolactin levels
was restricted to a sample of postmenopausal women
only. Nonetheless, in that study, prolactin levels varied
by genotype for risk-associated SNP rs9466314, but not
rs34024951 [19].
It is likely that SNP-related variations in prolactin do
not translate directly into altered disease risk and that
other biological factors are at play. Several breast cancer
risk factors have been reported to be associated with
prolactin levels [29] (reviewed in [14]), and estrogen has
been shown to stimulate the PRL extrapituitary promo-
ter in breast cancer cell lines [30]. Furthermore, prolac-
tin acts through both autocrine and endocrine pathways
(reviewed in [2]). Refinement of tissue-level prolactin
and prolactin receptor expression assays may provide a
more accurate estimate of the prolactin levels surround-
ing breast epithelial cells from autocrine and endocrine
sources.
Interpretation of our results was limited by the lack of
a validation population and by lack of overlap between
S N P sg e n o t y p e di no u ra n dp r e v i o u sPRL and PRLR
SNP studies. Thus, confirmation in other populations is
necessary. The results from Bogorad and colleagues [17]
and Lee and colleagues [19] suggest that study of rare
variants may show more promise than evaluation of
common variants only. Collaboration and pooled ana-
lyses may be the best ways to analyze alleles with a pre-
valence of less than 5% with sufficient statistical power.
Additionally, SNP rs7735260 had low concordance, indi-
cating that genotype calls for this SNP may not be
reliable. However, the high concordance rates among
the subset of samples that were genotyped in duplicate
indicate that genotyping was generally consistent for
other SNPs in the study.
A major strength of this study was the measurement
of serum prolactin levels. This allowed us to examine
relationships between circulating prolactin levels and
risk alleles, addressing the hypothesis that risk alleles
have a measurable effect on circulating prolactin levels.
Additionally, we conducted this analysis within a large,
population-based case-control study. The range of pro-
lactin levels in controls is representative of prolactin
concentrations among women in the general Polish
population. As discussed above, prolactin concentrations
in the breast may differ from circulating concentrations.
Measurement of prolactin in breast tissue may provide
additional information about the link between PRL and
PRLR genetics and breast cancer risk.
Conclusions
We found limited evidence for a relationship between
common genetic variants in PRL or PRLR and breast
cancer. Future studies should be conducted in ethnically
diverse populations and should have sufficient sample
size to study rare variants.
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